Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

Inclusion Criteria:

• Participant has completed participation of the 24-week double-blind treatment periodin Study URO-901-3005 (NCT03902080) and demonstrated compliance with the studyprocedures and study medication schedule in the opinion of the investigator.

• Participant is capable of giving written informed consent, which includes compliancewith the requirements and restrictions listed in the consent form.

• Participant has the ability to continue to receive a stable dose of Benign ProstaticHyperplasia (BPH) treatment with either a) alpha blocker monotherapy or b) alphablocker +5-ARI.

• In the opinion of the investigator, the participant is able and willing to complywith the requirements of the protocol, including completing study questionnaires andthe Bladder Diary.

Exclusion Criteria:

• Participant experienced any Serious Adverse Event in Study URO-901-3005 that wasreported as "possibly or probably related" to study treatment by the investigator.

• Participant is using any prohibited medications

• Participant has uncontrolled hyperglycemia (defined as fasting blood glucose >150milligrams per deciliter [mg/dL] or 8.33 millimoles per Liter [mmol/L] and/ornon-fasting blood glucose >200 mg/dL or 11.1 mmol/L) based on most recent availablelab results in Study URO-901-3005 or uncontrolled in the opinion of theinvestigator.

• Participant has uncontrolled hypertension (systolic blood pressure of ≥180millimeters of mercury [mmHg] and/or diastolic blood pressure of ≥100 mmHg) or has aresting heart rate (by pulse) >100 beats per minute.

• Participant has systolic blood pressures ≥160 mmHg but <180 mmHg, unless deemed bythe investigator as safe to proceed in this study and able to complete the study perprotocol.

• Participant has current evidence of any clinically significant condition, therapy,lab abnormality, or other circumstances that might, in the opinion of theinvestigator, confound the results of the study, interfere with the participant'sability to comply with study procedures, or make participation in the study not inthe participant's best interest.